Premium
Proteomic studies on receptor for advanced glycation end product variants in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease
Author(s) -
Ohlmeier Steffen,
Mazur Witold,
Salmenkivi Kaisa,
Myllärniemi Marjukka,
Bergmann Ulrich,
Kinnula Vuokko L.
Publication year - 2010
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.200900128
Subject(s) - rage (emotion) , idiopathic pulmonary fibrosis , bronchoalveolar lavage , medicine , copd , glycation , lung , advanced glycation end product , immunology , receptor , pathology , biology , neuroscience
Purpose: Proteomic screening revealed declined levels of the receptor for advanced glycation end products (RAGE) in human idiopathic pulmonary fibrosis (IPF). This study was undertaken to investigate the different RAGE isoforms in two lung diseases with destruction of the lung parenchyma, i.e . IPF and chronic obstructive pulmonary disease (COPD). Experimental design: RAGE was analyzed by 2‐DE, MS and Western blotting using lung tissues from non‐smokers, smokers, patients with IPF, COPD and α‐1‐antitrypsin deficiency (AAT) and by ELISA from the bronchoalveolar lavage fluid samples. Results: RAGE, detected by 2‐DE in the control lung, was confirmed to be glycosylated, soluble, C‐truncated RAGE with characteristics indicative of the presence of endogenous secretory RAGE (esRAGE). Further studies revealed a decrease of the full length‐RAGE (FL‐RAGE) and its C‐terminal processed variant (cRAGE) in the lung tissues of IPF and COPD patients but not in AAT. The esRAGE level was reduced in IPF but was unchanged in COPD. Conclusions and clinical relevance: This study shows an involvement of the three RAGE variants (FL‐RAGE, cRAGE, esRAGE) in IPF. The decline of FL‐RAGE and cRAGE, but not esRAGE, in COPD lungs is evidence of involvement of specific RAGE variants also in this disease.